Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Probenecid on Pexidartinib PK
NCT03138759Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2017
- Primary completion
- Mar 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pexidartinib in tenosynovial giant cell tumor (TGCT) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Concentration and 1 more. Started Feb 2017; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT03138759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138759.